Rezolute receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Pipeline Progress | Explore Rezolute's promising clinical trials for ersodetug in hyperinsulinism and RZ402 for diabetic macular edema, with key results expected in 2025-2026. |
Financial Strength | Delve into Rezolute's robust financial position, with $118 million in cash and a strong current ratio, supporting ongoing clinical programs. |
Market Opportunities | Learn about Rezolute's potential in niche markets, including congenital hyperinsulinism and diabetic macular edema, with oral administration as a key advantage. |
Analyst Outlook | Discover varied analyst perspectives on Rezolute, with price targets ranging from $7 to $9, reflecting the company's growth potential in metabolic diseases. |
Metrics to compare | RZLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRZLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −2.4x | −0.4x | |
PEG Ratio | −0.22 | −0.02 | 0.00 | |
Price/Book | 4.1x | 4.2x | 2.6x | |
Price / LTM Sales | - | 19.3x | 3.0x | |
Upside (Analyst Target) | 113.7% | 118.1% | 58.0% | |
Fair Value Upside | Unlock | 4.1% | 7.8% | Unlock |
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.